Concepedia

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn, Patrick M. Boland, Kristen K. Ciombor, Erica N. Heying, Travis Dockter, Nisha L. Jacobs, Boris Pasche, James M. Cleary,

The Lancet Oncology · 2019 · 284 citations · 16 references

DOIFull text

Open access

Concepts

References

16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 87.7K citations · Full text

, , +16

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey, Eric Van Cutsem, Alberto Sobrero et al. · The Lancet · 2012 · 2.9K citations

, , +10

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Stuart Pocock, Richard Simon · Biometrics · 1975 · 2.4K citations

, , +12

The rapid assessment of fatigue severity in cancer patients

Tito R. Mendoza, X. Shelley Wang, Charles S. Cleeland et al. · Cancer · 1999 · 1.8K citations · Full text

, , +16